Debra Kimless, M.D. graduated magna cum laude, Phi Beta Kappa from Muhlenberg College with a double major in Natural Sciences and Biology. She attended medical school at Rutgers, and residency at Temple University Hospital and is a board certified Anesthesiologist with a subspecialty certification in Pain Medicine.
Motivated by her mother who suffered with intractable pain at the end of her life and responded paradoxically to opiates, Dr. Kimless traveled the world studying under the most respected experts in cannabis medicine and research and became a passionate champion for medical cannabis.
In addition to being the Medical Director of ForwardGro, a medical cannabis cultivation and processing company in Maryland, Dr. Kimless shares her knowledge by speaking with physicians and other health care providers, patients and legislators to educate about the endocannabinoid system, medical applications of cannabis, methods of administration and why it matters, as well as cannabis as a harm reduction tool. She consults with patients, pro bono and collects patient data and presents the cases at national and international conferences and seminars.
Her passion is to use education to de-stigmatize cannabis and explain how it may be used as an effective medical therapeutic choice.
There has been no new treatment for mild to moderate pain since the release of prescription ibuprofen in 1974, naproxen in 1976, and naproxen sodium in 1980. Off label uses of medications for the treatment of pain include SSRIs, SNRIs, and anti-seizure medications. These medications have proven to be inconsistent in their pain-relieving efficacy. Opioids should be reserved for treating severe refractory pain, but current evidence of widespread opioid abuse and opioid related deaths reveal that opioids are being used for other types of pain. Failure to adequately manage pain may lead to widespread multisystem deleterious effects involving the immune, endocrine, cardiovascular, neurologic, psychologic, gastro-intestinal and musculo-skeletal systems and a diminished quality of life as well as a potential cause of opioid use disorder. Cannabis and cannabinoids have been reported in the literature to be useful for the treatment of refractory chronic pain as well to reduce or replace opioids for pain management. We will discuss the results of an initial proof of concept trial and then an expanded multi-site trial using a novel non-intoxicating formulation of whole plant extract of cannabinoids.